
The College of American Pathologists and the University of Pittsburgh's Computational Pathology and AI Center of Excellence have struck a strategic partnership aimed at bringing artificial intelligence tools to pathologists and laboratory professionals across the country. The agreement centers on two AI platforms built through Pitt's center, with organizers framing the work as exploratory rather than a rollout of finished products.
A Pittsburgh-Born AI Center Teams Up With a National Pathology Group
According to Clinical Lab Products, the partnership is designed to advance AI solutions for CAP members and for pathology and laboratory communities more broadly. The two cornerstone platforms named in the announcement are Nebulon-GPT-Plus, also referred to as Pitt-GPT-Plus, and Pitt-AI-cademy, both developed through Pitt's Computational Pathology and AI Center of Excellence, known as CPACE. The center describes itself, per the same report, as one of the world's first and largest hubs dedicated specifically to AI in pathology.
CPACE itself is a joint venture between the University of Pittsburgh and UPMC, built to bring together experts in computational pathology and AI to collaborate on research and education, according to the University of Pittsburgh's health sciences office. The center says it was established in January 2024, per CPACE's own site.
What the Two AI Platforms Are Built to Do
Nebulon-GPT-Plus is described as a conversational platform that uses large language models and knowledge retrieval technologies to deliver what the announcement calls context-aware assistance, the report notes. The platform is meant to provide a scalable foundation for specialized AI assistants capable of working with complex, domain-specific information, and to support the development and deployment of customized AI solutions down the line.
Pitt-AI-cademy, the second platform, is pitched as an interactive, no-code AI education tool designed for learners with a broad range of technical backgrounds and experience levels. Together, the two platforms are expected to support practical AI applications, AI literacy, workforce readiness, and innovation across the pathology field, the article states. CAP president Qihui “Jim” Zhai said the organization's exploration of AI will aim to improve CAP's operations, organizational capabilities, and member services, adding that opportunities will be assessed with rigorous evaluation, human oversight, data security, and responsible governance.
Potential Uses Still Under Exploration, Not Yet Deployed
The announcement lists several possible applications CAP may explore rather than confirming any are already running. Those include intelligent navigation of educational resources, enhanced knowledge management, AI-assisted access to information on laboratory quality, accreditation, and professional practice, and support for internal administrative workflows. The partnership will also explore additional AI platforms for operational analytics, workflow automation, and decision support, per the same report.
CAP describes itself as the world's largest organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs. Under the partnership, CAP is contributing its expertise in laboratory accreditation, quality improvement, education, and advocacy, while CPACE brings its expertise in applied AI. Any resulting AI applications are intended to align with CAP's organizational requirements and member expectations, and development and adoption are set to be guided by governance, data security, performance evaluation, human oversight, and ongoing monitoring.
A Field Where AI Adoption Still Lags
The timing lands against a backdrop of uneven AI uptake in clinical laboratories more broadly. In an international survey of laboratory professionals experienced with AI, only about a third could identify an application actually operating in their own lab, according to CAP Today. That survey drew 50 complete responses — 18 from Europe, 18 from the United States, seven from Canada, six from Asia, and one from Africa — and its authors concluded that implementation remains limited and highly inconsistent, with most clinical labs lacking the in-house expertise to build their own models.
The same survey pointed to insufficient information technology infrastructure and a lack of practical implementation guidelines as the leading obstacles to adoption. Regulatory presence remains thin too: as of June 2026, just 21 of the 1,525 FDA-authorized AI-enabled medical devices were in laboratory medicine, roughly 1.4% of the total, CAP Today reported.
Digital Pathology Adoption Also Varies Widely
Digital pathology, a related but distinct technology that underpins much AI work in the field, shows a similarly mixed picture. An international survey of 127 laboratories conducted in 2023 found 57% had implemented digital pathology for research or clinical purposes, according to a report in the Journal of Pathology and Translational Medicine. By contrast, a 2024 CAP estimate put digital pathology adoption at only around 10% among U.S. labs specifically, the same journal noted. CAP recommends validating digital pathology workflows with at least 60 cases and achieving greater than 95% consistency between whole-slide image and glass-slide reads, per that report.
Part of a Broader Wave of Pathology AI Partnerships
The CAP-CPACE agreement follows a string of other collaborations reshaping digital pathology and AI. Weeks earlier, on October 23, CAP and the Digital Pathology Association announced their own partnership, governed by a memorandum of understanding running through 2029, according to a CAP announcement. That collaboration is set to focus on digital pathology interoperability and standards, workforce development and education, advocacy, reimbursement resources, and verification frameworks for whole-slide imaging and AI tools, with potential activities including new guidance and resources to support clinical adoption.
CPACE has also been building infrastructure for AI development beyond the CAP partnership. In December 2025, the center partnered with Leidos on the ScanVan, a relocatable container designed to digitize pathology slides, with the resulting images intended for education, clinical research, and AI development, according to CPACE. Separately, digital pathology vendors have been striking their own commercial deals: Aiforia entered into a commercial agreement with PathAI to make its AI solutions available to clinical laboratories through the AISight Marketplace, with Aiforia's image-analysis tools set to integrate directly into PathAI's AISight Dx Image Management System, per Clinical Lab Products.









